JIN-A02 — Investigational Agent
EGFR Inhibitor · Phase 1/2 · J INTS BIO
Mechanism of Action
JIN-A02 is a fourth-generation oral EGFR tyrosine kinase inhibitor engineered to inhibit EGFR harboring the C797S resistance mutation, including complex triple-mutant alleles (activating mutation + T790M + C797S) that render tumors resistant to first-, second-, and third-generation EGFR TKIs such as osimertinib. It targets both cis and trans C797S/T790M configurations while retaining activity against classic activating mutations. The compound is also designed for central nervous system penetration to address brain metastases common in EGFR-mutant NSCLC.
Investigational Indications
- EGFR-mutant NSCLC with C797S resistance after prior EGFR TKI
- EGFR-mutant NSCLC with brain metastases